-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
August 2019
-
Can E-Cigarettes Help Patients Stop Smoking Combustible Cigarettes?
By Li-Shiun Chen, MD, MPH, ScD, and Laura J. Bierut, MD Posted: August 14, 2019 Dr. Li-Shiun Chen Dr. Laura J. Bierut Combustible tobacco products, primarily cigarettes, continue to be the leading cause of cancer, and in the most recent surveys, an estimated 34.3 million adults smoke (14% of the U.S. adult population).1 Whereas combustible cigarette…
-
Accessing Lung Cancer Experts from Anywhere in the World
Posted: August 14, 2019 People diagnosed with lung cancer do not have to live close to a major cancer center to get a second opinion from one of its experts, thanks to a growing number of remote second-opinion (RSO) programs. “What is offered in remote second-opinion programs can vary, but the one commonality is that the…
-
Special Session to Honor Dr. Adi Gazdar
By Ignacio Wistuba, MD, and John Minna, MD Posted: August 14, 2019 Dr. Adi Gazdar was a scientific pioneer, a groundbreaking pathologist, a loyal friend, and an inspiring mentor. Dr. Gazdar was born in India; he earned his medical degree from Guy’s Hospital Medical School at the University of London and completed residencies in pathology at…
-
JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit
By Hossein Borghaei, DO, MS Posted: August 14, 2019 In 2015, the use of checkpoint inhibitors in the second-line setting for metastatic lung cancer became the standard of care with the approval first of nivolumab followed by pembrolizumab and later atezolizumab. In all randomized trials with these agents, the comparator arm was docetaxel because it represented…
-
First School of Nursing to Be Held at 2019 Latin American Conference on Lung Cancer
By Enza Esposito Nguyen, DNP, RN, ANP-BC, AOCNP Posted: August 14, 2019 Dr. Enza Esposito Nguyen The upcoming ninth Latin American Conference on Lung Cancer—to be held in Mexico City, Mexico, in October 2019, and sponsored by the IASLC Latin American Group (LATAM)—will feature, for the first time, a notable, overdue addition: the first School of…
-
Christian Rolfo, MD, PhD, MBA, Dr.h.c.
Posted: August 14, 2019 Christian Rolfo, MD, PhD, MBA, Dr.h.c., was recently appointed vice president of The International Society of Liquid Biopsy (ISLB). This nonprofit organization, founded in 2017, aims to erase restrictions of liquid biopsy implementation in routine clinical practice, either in individual countries or across specialties. The society will hold its annual congress April…
-
Improving Lung Nodule Evaluation Through Identification of Additional Features
By David Yankelevitz, MD Posted: August 14, 2019 IN REFERENCE TO: Peikert T, Rajagopalan S, Karwoski RA, et al. Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening Trial. PLoS One. 2018;13(10). e0196910 The article “Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening…
View ILCN Archives
Provider Resources
Popular Articles